| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
CLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing |
| 26 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Forward Looking Statements This presentation contains “forward-looking statements” including, without limitation, statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefi... |
| 23 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 |
| 03 Sep 2026 |
8-K: Regulation FD Disclosure
R&D Spotlight: CLYM116 Initial Phase 1 Results September 3, 2026 Exhibit 99.2 |
| 14 Aug 2026 |
8-K: Other Events
On August 13, 2026, Beijing Mabworks Biotech Co., Ltd. announced the dosing of the first patient with immunoglobulin A nephropathy in a Phase 2 clinical trial in China, which is being conducted in collaboration with Climb Bio, Inc. |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 |
| 01 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Climb Bio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the... |
| 11 Jun 2026 |
8-K: Other Events
On June 11, 2026, Climb Bio, Inc. (the “Company”) announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (... |
| 08 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) any Returning Shares will beco... |
| 05 Jun 2026 |
8-K: Other Events
On June 5, 2026, Climb Bio, Inc. (the “Company”) announced translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, its anti-APRIL monoclonal antibody: |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development |
| 05 May 2026 |
8-K: Regulation FD Disclosure
R&D Spotlight: Budoprutug and the CD19 Opportunity MAY 5, 2026 Exhibit 99.2 |
| 28 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 27, 2026, by and among Climb Bio, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an ... |
| 03 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 |
| 08 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 |
| 31 Dec 2025 |
8-K: Other Events
Plaintiff Climb Bio, Inc. (“Climb”), by and through its undersigned counsel, hereby alleges as and for its complaint against Alumis Inc. (“Alumis”) and Acelyrin, Inc. (“Acelyrin”) (collectively, “Defendants” or “Alumis”), upon knowledge ... |
| 11 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE O... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated |
Loading...